Literature DB >> 9181529

Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups.

T Poynard1, P Bedossa.   

Abstract

The aim of this study was to identify clinical and biological factors associated with histological lesions in patients with chronic hepatitis C and to construct a simple diagnostic index. A database consisting of 500 patients with untreated biopsy-proven chronic non-A non-B hepatitis was used. Liver biopsies were reviewed, blind, by a panel of pathologists. Patients were classified according to the presence of necroinflammatory lesions (histological activity) and fibrosis. The diagnostic value of nine clinical and 10 biological factors was assessed using logistic regression analysis, sensitivity, specificity and predictive values, and a score was constructed combining the most significant factors identified. The validation used an independent population of 120 patients. Serum platelet concentration and age were the two main factors significantly and independently correlated with the presence of fibrosis and/or histological activity. A simple score referred to as AP, combining age and platelet count, varied from 0-10. For the presence of significant histological disease (moderate to severe necroinflammatory lesions and/or septal fibrosis to cirrhosis), an AP score of 6 or more had a specificity of 0.93 and a sensitivity of 0.52%. In the validation population, the area under the curve was 0.690 +/- 0.085, not significantly different from that of the first population, 0.763 +/- 0.043. Hence, a simple score combining age and platelet count enabled the accurate prediction of the presence of activity and fibrosis in patients infected with the hepatitis C virus. When this score reached 6, liver biopsy could be avoided owing to its high predictive value. However, the negative predictive value was not high enough to prevent a liver biopsy in patients with a lower score.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9181529     DOI: 10.1046/j.1365-2893.1997.00141.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  57 in total

1.  Simple tests to predict hepatic fibrosis in nonalcoholic chronic liver diseases.

Authors:  Woon Geon Shin; Sang Hoon Park; Sun-Young Jun; Jae One Jung; Joon Ho Moon; Jong Pyo Kim; Kyoung Oh Kim; Cheol Hee Park; Tai Ho Hahn; Kyo-Sang Yoo; Jong Hyeok Kim; Choong Kee Park
Journal:  Gut Liver       Date:  2007-12-31       Impact factor: 4.519

2.  A new index for non-invasive assessment of liver fibrosis.

Authors:  Naohiro Ichino; Keisuke Osakabe; Toru Nishikawa; Hiroko Sugiyama; Miho Kato; Shiho Kitahara; Senju Hashimoto; Naoto Kawabe; Masao Harata; Yoshifumi Nitta; Michihito Murao; Takuji Nakano; Yuko Arima; Hiroaki Shimazaki; Koji Suzuki; Kentaro Yoshioka
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

3.  Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression.

Authors:  Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Eun Hee Choi; Jae Yeon Seok; Jung Min Lee; Young Nyun Park; Chae Yoon Chon; Kwang-Hyub Han
Journal:  Hepatol Int       Date:  2010-08-04       Impact factor: 6.047

4.  Platelet count for predicting fibrosis in nonalcoholic fatty liver disease.

Authors:  Masato Yoneda; Hideki Fujii; Yoshio Sumida; Hideyuki Hyogo; Yoshito Itoh; Masafumi Ono; Yuichiro Eguchi; Yasuaki Suzuki; Noriaki Aoki; Kazuyuki Kanemasa; Kento Imajo; Kazuaki Chayama; Toshiji Saibara; Norifumi Kawada; Kazuma Fujimoto; Yutaka Kohgo; Toshikazu Yoshikawa; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2011-07-13       Impact factor: 7.527

5.  Clinical Utility of Biomarkers of Liver Fibrosis.

Authors:  Keyur Patel; Don C Rockey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

6.  Value of shear wave velocity measurements for the risk assessment of hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease : HCC risk assessment by VTTQ.

Authors:  Masaaki Takamura; Tsutomu Kanefuji; Takeshi Suda; Takeshi Yokoo; Hiroteru Kamimura; Atsunori Tsuchiya; Kenya Kamimura; Yasushi Tamura; Masato Igarashi; Hirokazu Kawai; Satoshi Yamagiwa; Minoru Nomoto; Yutaka Aoyagi
Journal:  Hepatol Int       Date:  2014-03-01       Impact factor: 6.047

7.  Non invasive tools for the diagnosis of liver cirrhosis.

Authors:  Maurizio Soresi; Lydia Giannitrapani; Melchiorre Cervello; Anna Licata; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

8.  Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.

Authors:  Robert P Myers; Mercedes De Torres; Françoise Imbert-Bismut; Vlad Ratziu; Frédéric Charlotte; Thierry Poynard
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

9.  External validation of P2/MS and comparison with other simple non-invasive indices for predicting liver fibrosis in HBV-infected patients.

Authors:  Beom Kyung Kim; Kwang Hyub Han; Jun Yong Park; Sang Hoon Ahn; Chae Yoon Chon; Ja Kyung Kim; Yong Han Paik; Kwan Sik Lee; Young Nyun Park; Do Young Kim
Journal:  Dig Dis Sci       Date:  2009-12-04       Impact factor: 3.199

10.  Usefulness of non-invasive markers for predicting significant fibrosis in patients with chronic liver disease.

Authors:  Han Hyo Lee; Yeon Seok Seo; Soon Ho Um; Nam Hee Won; Hanna Yoo; Eun Suk Jung; Yong Dae Kwon; Sanghoon Park; Bora Keum; Yong Sik Kim; Hyung Joon Yim; Yoon Tae Jeen; Hoon Jai Chun; Chang Duck Kim; Ho Sang Ryu
Journal:  J Korean Med Sci       Date:  2009-12-26       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.